Of sound mind and body: Depression, disease, and accelerated aging

Dialogues in Clinical Neuroscience

Volumn 13, Issue 1, 2011, Pages 25-40

  Wolkowitz, Owen M ^a   Reus, Victor I ^a   Mellon, Synthia H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Childhood adversity; Cortisol; Depression; Inflammation; Oxidative stress; Telomere

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; ANTIDEPRESSANT AGENT; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; BRAIN DERIVED NEUROTROPHIC FACTOR; CALCIUM CHANNEL BLOCKING AGENT; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; GLUCOCORTICOID; GLUCOCORTICOID ANTAGONIST; GLUCOCORTICOID RECEPTOR; GLUTAMIC ACID; HYDROCORTISONE; INSULIN RECEPTOR; INSULIN SENSITIZING AGENT; NEUROSTEROID; NEUROTRANSMITTER; PRASTERONE; SEROTONIN UPTAKE INHIBITOR; TELOMERASE; TELOMERASE INHIBITOR;

AGED; AGING; APOPTOSIS; ARTICLE; CALCIUM CELL LEVEL; CARDIOVASCULAR DISEASE; CELL AGING; CELL DEATH; CHILD ABUSE; COMORBIDITY; COPING BEHAVIOR; DEMENTIA; DEPRESSION; DIABETES MELLITUS; DIET RESTRICTION; DIET SUPPLEMENTATION; DNA MODIFICATION; ENVIRONMENTAL ENRICHMENT; ENZYME ACTIVATION; EXCITOTOXICITY; EXERCISE; GENETIC PREDISPOSITION; GLUCOSE TOLERANCE; HUMAN; IMMUNE SYSTEM; INSULIN SENSITIVITY; LIFE EVENT; LIFE STRESS; LIFESTYLE MODIFICATION; MAJOR DEPRESSION; MATERNAL DISEASE; MEDITATION; MENTAL STRESS; METABOLIC SYNDROME X; OSTEOPOROSIS; OXIDATIVE STRESS; PHYSICAL DISEASE; PREMENSTRUAL DYSPHORIC DISORDER; RELAXATION TRAINING; SUICIDE; TELOMERE; BIOLOGICAL MODEL; BRAIN LEVEL; EPIGENETICS; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; LIMBIC SYSTEM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGICAL ASPECT; REVIEW;

AGING; BRAIN CHEMISTRY; DEPRESSIVE DISORDER, MAJOR; EPIGENOMICS; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; IMMUNE SYSTEM; LIMBIC SYSTEM; MODELS, BIOLOGICAL; PITUITARY-ADRENAL SYSTEM;

EID: 79955826399     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (158)

1. Heuser I. Depression, endocrinologically a syndrome of premature aging? Maturitas. 2002;41(suppl 1):S19-S23.
2. McIntyre RS, Soczynska JK, Konarski JZ, et al. Should depressive syndromes be reclassified as "metabolic syndrome type II"? Ann Clin Psychiatry. 2007;19:257-264.
3. Evans DL, Charney DS, Lewis L, et al. Mood disorders in the medically ill: scientific review and recommendations. Biol Psychiatry. 2005;58:175-189.
4. Schulz R, Beach SR, Ives DG, Martire LM, Ariyo AA, Kop WJ. Association between depression and mortality in older adults: the Cardiovascular Health Study. Arch Intern Med. 2000;160:1761-1768.
5. Wolkowitz OM, Epel ES, Mellon S. When blue turns to grey: do stress and depression accelerate cell aging? World J Biol Psychiatry. 2008;9:2-5.
6. Wolkowitz OM, Epel ES, Reus VI, Mellon SH. Depression gets old fast: do stress and depression accelerate cell aging? Depression and Anxiety. 2010;27:327-338.
7. Epel ES. Psychological and metabolic stress: a recipe for accelerated cellular aging? Hormones (Athens). 2009;8:7-22.
8. Epel ES, Blackburn EH, Lin J, et al. Accelerated telomere shortening in response to life stress. Proc Natl Acad Sci U S A. 2004;101:17312-17315.
9. Epel ES, Lin J, Wilhelm FH, et al. Cell aging in relation to stress arousal and cardiovascular disease risk factors. Psychoneuroendocrinology. 2006;31:277-287.
10. Wolkowitz OM, Epel ES, Reus VI. Stress hormone-related psychopathology: pathophysiological and treatment implications. World J Biol Psychiat. 2001;2:115-143.
11. Selye H. The Stress of Life. New York, NY: McGraw-Hill; 1956.
12. Seeman T, McEwen BS, Rowe J, Singer B. Allostatic load as a marker of cumulative biological risk: MacArthur studies of successful aging. Proc Natl Acad Sci U S A. 2001;9:4770-4775.
13. McEwen B. Allostasis and allostatic load: implications for neuropsychopharmacology. Neuropsychopharmacology. 2000;22:108-124.
14. Schulkin J, McEwen BS, Gold PW. Allostasis, amygdala, and anticipatory angst. Neurosci Biobehav Rev. 1994;18:385-396.
15. Wong ML, Kling MA, Munson PJ, et al. Pronounced and sustained central hypernoradrenergic function in major depression with melancholic features: relation to hypercortisolism and corticotropin-releasing hormone. Proc Natl Acad Sci U S A. 2000;97:325-330.
16. Sapolsky RM. The possibility of neurotoxicity in the hippocampus in major depression: a primer on neuron death. Biol Psychiatry. 2000;48:755-765.
17. Maninger N, Wolkowitz OM, Reus VI, Epel ES, Mellon SH. Neurobiological and neuropsychiatric effects of dehydroepiandrosterone (DHEA) and DHEA sulfate (DHEAS). Front Neuroendocrinol. 2009;30:65-91.
18. Patchev VK, Hassan AH, Holsboer DF, Almeida OF. The neurosteroid tetrahydroprogesterone attenuates the endocrine response to stress and exerts glucocorticoid-like effects on vasopressin gene transcription in the rat hypothalamus. Neuropsychopharmacology. 1996;15:533-540.
19. Kendler K, Karkowski LM, Prescott CA. Causal relationship between stressful life events and the onset of major depression. Am J Psychiatry. 1999;156:837-841.
20. Raison CL, Miller AH. When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. Am J Psychiatry. 2003;160:1554-1565.
21. Folkman S, Lazarus RS, Dunkel-Schetter C, DeLongis A, Gruen RJ. Dynamics of a stressful encounter: cognitive appraisal, coping, and encounter outcomes. J Pers Soc Psychol. 1986;50:992-1003.
22. O'Donovan A, Lin J, Dhabhar FS, et al. Pessimism correlates with leukocyte telomere shortness and elevated interleukin-6 in post-menopausal women. Brain Behav Immun. 2009;23:446-449.
23. Denson TF, Spanovic M, Miller N. Cognitive appraisals and emotions predict cortisol and immune responses: a meta-analysis of acute laboratory social stressors and emotion inductions. Psychol Bull. 2009;135:823-853.
24. Stowell JR, Kiecolt-Glaser JK, Glaser R. Perceived stress and cellular immunity: when coping counts. J Behav Med. 2001;24:323-339.
25. Lyons DM, Buckmaster PS, Lee AG, et al. Stress coping stimulates hippocampal neurogenesis in adult monkeys. Proc Natl Acad Sci U S A. 2010;107:14823-14827.
26. Taylor SE, Burklund LJ, Eisenberger NI, et al. Neural bases of moderation of cortisol stress responses by psychosocial resources. J Pers Soc Psychol. 2008;95:197-211.
27. Breier A, Kelsoe JR Jr, Kirwin PD, et al. Early parental loss and development of adult psychopathology. Arch Gen Psychiatry. 1988;45:987-993.
28. Feder A, Nestler EJ, Charney DS. Psychobiology and molecular genetics of resilience. Nat Rev Neurosci. 2009;10:446-457.
29. Chapman DP, Whitfield CL, Felitti VJ, et al. Adverse childhood experiences and the risk of depressive disorders in adulthood. J Affect Disord. 2004;82:217-225.
30. Heim C, Plotsky PM, Nemeroff CB. Importance of studying the contributions of early adverse experience to neurobiological findings in depression. Neuropsychopharmacology. 2004;29:641-648.
31. Grassi-Oliveira R, Ashy M, Stein LM. Psychobiology of childhood maltreatment: effects of allostatic load? Rev Bras Psiquiatr. 2008;30:60-68.
32. Vythilingam M, Heim C, Newport J, et al. Childhood trauma associated with smaller hippocampal volume in women with major depression. Am J Psychiatry. 2002;159:2072-2080.
33. Miller JM, Kinnally EL, Ogden RT, et al. Reported childhood abuse is associated with low serotonin transporter binding in vivo in major depressive disorder. Synapse. 2009;63:565-573.
34. Anda RF, Felitti VJ, Bremner JD, et al. The enduring effects of abuse and related adverse experiences in childhood: A convergence of evidence from neurobiology and epidemiology. Eur Arch Psychiatry Clin Neurosci. 2006;256:174-186.
35. Pace TW, Mletzko TC, Alagbe O, et al. Increased stress-induced inflammatory responses in male patients with major depression and increased early life stress. Am J Psychiatry. 2006;163:1630-1633.
36. Kiecolt-Glaser JK, Gouin JP, Weng NP, et al. Childhood adversity heightens the impact of later-life caregiving stress on telomere length and inflammation. Psychosom Med 2010;73:16-22.
37. Barnes SK, Ozanne SE. Pathways linking the early environment to longterm health and lifespan. Prog Biophys Mol Biol. In press.
38. Roth TL, Lubin FD, Funk AJ, Sweatt JD. Lasting epigenetic influence of early-life adversity on the BDNF gene. Biol Psychiatry. 2009;65:760-769.
39. Avital A, Ram E, Maayan R, Weizman A, Richter-Levin G. Effects of early-life stress on behavior and neurosteroid levels in the rat hypothalamus and entorhinal cortex. Brain Res Bull. 2006;68:419-424.
40. Thomas C, Hypponen E, Power C. Obesity and type 2 diabetes risk in midadult life: the role of childhood adversity. Pediatrics. 2008;121, e1240-e1249.
41. Wolkowitz OM, Epel ES, Mellon SH, et al. Major depression and history of childhood sexual abuse are related to increased PBMC telomerase activity. in International Society of Psychoneuroendocrinology Annual Meeting. San Francisco, CA, 2009.
42. Kananen L, Surakka I, Pirkola S, et al. Childhood adversities are associated with shorter telomere length at adult age both in individuals with an anxiety disorder and controls. PLoS One. 2010;5:e10826.
43. Tyrka AR, Price LH, Kao HT, Porton B, Marsella SA, Carpenter LL. Childhood maltreatment and telomere shortening: preliminary support for an effect of early stress on cellular aging. Biol Psychiatry. 2010;67:531-534.
44. O'Donovan, A, Epel ES, Lin J, et al. Childhood trauma associated with short leukocyte telomere length in post-traumatic stress disorder. Biol Psychiatry. 2011. In press.
45. McGowan PO, Sasaki A, D'Alessio AC, et al. Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse. Nat Neurosci. 2009;12:342-348.
46. Weaver IC, Cervoni N, Champagne FA, et al. Epigenetic programming by maternal behavior. Nat Neurosci. 2004;7:847-854.
47. Krishnan V, Nestler EJ. Linking molecules to mood: new insight into the biology of depression. Am J Psychiatry. 2010;167:1305-1320.
48. DeRijk R, de Kloet ER. Corticosteroid receptor genetic polymorphisms and stress responsivity. Endocrine. 2005;28:263-270.
49. Wasserman D, Wasserman J, Sokolowski M. Genetics of HPA-axis, depression and suicidality. Eur Psychiatry. 2010;25:278-280.
50. Schroeder M, Krebs MO, Bleich S, Frieling H. Epigenetics and depression: current challenges and new therapeutic options. Curr Opin Psychiatry. 2010;23:588-592.
51. Korosi A, Shanabrough M, McLelland S, et al. Early-life experience reduces excitation to stress-responsive hypothalamic neurons and reprograms the expression of corticotropin-releasing hormone. J Neurosci. 2010;30:703-713.
52. Murgatroyd C, Patchev AV, Wu Y, et al. Dynamic DNA methylation programs persistent adverse effects of early-life stress. Nat Neurosci. 2009;12:1559-1566.
53. Oberlander TF, Weinberg J, Papsdorf M, Grunau R, Misri S, Devlin AM. Prenatal exposure to maternal depression, neonatal methylation of human glucocorticoid receptor gene (NR3C1) and infant cortisol stress responses. Epigenetics. 2008;3:97-106.
54. Tyrka AR, Price LH, Gelernter J, Schepker C, Anderson GM, Carpenter LL. Interaction of childhood maltreatment with the corticotropin-releasing hormone receptor gene: effects on hypothalamic-pituitary-adrenal axis reactivity. Biol Psychiatry. 2009;66:681-685.
55. Chipman P, Jorm AF, Tan XY, Easteal S. No association between the serotonin-1A receptor gene single nucleotide polymorphism rs6295C/G and symptoms of anxiety or depression, and no interaction between the polymorphism and environmental stressors of childhood anxiety or recent stressful life events on anxiety or depression. Psychiatr Genet. 2010;20:8-13.
56. Caspi A, Sugden K, Moffitt TE, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science. 2003;301:386-389.
57. Karg K, Burmeister M, Shedden K, Sen S. The Serotonin transporter promoter variant (5-HTTLPR), stress, and depression meta-analysis revisited: evidence of genetic moderation. Arch Gen Psychiatry. In press.
58. Risch N, Herrell R, Lehner T, et al. Interaction between the serotonin transporter gene (5-HTTLPR), stressful life events, and risk of depression: a meta-analysis. JAMA. 2009;301:2462-2471.
59. Ressler KJ, Bradley B, Mercer KB, et al. Polymorphisms in CRHR1 and the serotonin transporter loci: gene x gene x environment interactions on depressive symptoms. Am J Med Genet B Neuropsychiatr Genet. 2010;153B:812-824.
60. Kaufman J, Yang BZ, Douglas-Palumberi H, et al. Brain-derived neurotrophic factor-5-HTTLPR gene interactions and environmental modifiers of depression in children. Biol Psychiatry. 2006;59:673-80.
61. Fries E, Hesse J, Hellhammer J, Hellhammer DH. A new view on hypocortisolism. Psychoneuroendocrinology. 2005;30:1010-1016.
62. Bremmer MA, Deek DJ, Beekman AT, Penninx BW, Lips P, Hoogendijk WJ. Major depression in late life is associated with both hypo- and hypercortisolemia. Biol Psychiatry. 2007;62:479-486.
63. Miller AH. Letter to the Editor Re: An inflammatory review of glucocorticoids in the CNS. Sorrells SF, Sapolsky RM. Brain Behavior Immun. 2007;21:259-272: Brain Behav Immun. 2007;21:988-989; author reply 990.
64. Sorrells SF, Sapolsky RM. A pro-inflammatory review of glucocorticoid actions in the CNS. Brain Behav Immun. 2007;21:259-272.
65. Miller KB, Nelson JC. Does the dexamethasone suppression test relate to subtypes, factors, symptoms, or severity? Arch Gen Psychiatry. 1987;44:769-
66. Arana GW, Santos AB, Laraia MT, et al. Dexamethasone for the treatment of depression: a randomized, placebo- controlled, double-blind trial. Am J Psychiatry. 1995;152:265-267.
67. Belanoff J, Schatzberg AF. Glucocorticoid antagonists. Neuropsychopharmacology. 2000;23:S56.
68. Wolkowitz OM, Reus VI. Treatment of depression with antiglucocorticoid drugs. Psychosomat Med. 1999;61:698-711.
69. Gallagher P, Watson S, Smith MS, Young AH, Ferrier IN. Antiglucocorticoid treatments for mood disorders. Cochrane Database Syst Rev. 2008 CD005168.
70. Frank MG, Miguel ZD, Watkins LR, Maier SF. Prior exposure to glucocorticoids sensitizes the neuroinflammatory and peripheral inflammatory responses to E. coli lipopolysaccharide. Brain Behav Immun. 2010;24:19-30.
71. Barden N, Reul JM, Holsboer F. Do antidepressants stabilize mood through actions on the hypothalamic-pituitary-adrenocortical system? Trends Neurosci. 1995 18:6-11.
72. Wolkowitz OM, Burke H, Epel ES, Reus VI. Glucocorticoids: mood, memory and mechanisms. Ann NY Acad Sci. 2009;1179:19-40.
73. Reus VI, Miner C. Evidence for physiological effects of hypercortisolemia in psychiatric patients. Psychiatry Res. 1985;14:47-56.
74. Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry. 2006;59:1116-1127.
75. Heim C, Ehlert U, Hellhammer DH. The potential role of hypocortisolism in the pathophysiology of stress-related bodily disorders. Psychoneuroendocrinology. 2000;25:1-35.
76. Uzunova V, Sheline Y, Davis JM, et al. Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Proc Natl Acad Sci U S A. 1998;95:3239-3244.
77. Griffin LD, Mellon, SH. Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes. Proc Natl Acad Sci. 1999;96:13512-13517.
78. Guidotti A, Costa E. Can the antidysphoric and anxiolytic profiles of selective serotonin reuptake inhibitors be related to their ability to increase brain allopregnanolone availability? Biol Psychiatry. 1998;44:865-873.
79. Bauer ME. Chronic stress and immunosenescence: a review. Neuroimmunomodulation. 2008;15:241-250.
80. Zampieri S, Mellon SH, Butters TD, et al. Oxidative stress in NPC1 deficient cells: protective effect of allopregnanolone. J Cell Mol Med. 2001;13:3786-3796.
81. Wang JM, Irwin RW, Liu L, Chen S, Brinton RD. Regeneration in a degenerating brain: potential of allopregnanolone as a neuroregenerative agent. Curr Alzheimer Res. 2007;4:510-517.
82. Strohle A, Romeo E, Hermann B, et al. Concentrations of 3a-reduced neuroactive steroids and their precursors in plasma of patients with major depression and after clinical recovery. Biol Psychiatry. 1999;45:274-277.
83. Rupprecht R. Neuroactive steroids: mechanisms of action and neuropsychopharmacological properties. Psychoneuroendocrinology. 2003;28:139-168.
84. Wolkowitz OM, Reus VI. Neurotransmitters, neurosteroids and neurotrophins: new models of the pathophysiology and treatment of depression. World J Biol Psychiatry. 2003;4:98-102.
85. Barbaccia ML, Serra M, Purdy RH, Biggio G. Stress and neuroactive steroids. Int Rev Neurobiol. 2001;46:243-272.
86. Calogero AE, Palumbo MA, Bosboom AM, et al. The neuroactive steroid allopregnanolone suppresses hypothalamic gonadotropin-releasing hormone release through a mechanism mediated by the gamma-aminobutyric acidA receptor. J Endocrinol. 1998;158:121-125.
87. Patchev VK, Shoaib M, Holsboer F, Almeida OF. The neurosteroid tetrahydroprogesterone counteracts corticotropin-releasing hormoneinduced anxiety and alters the release and gene expression of corticotropinreleasing hormone in the rat hypothalamus. Neuroscience. 1994;62:265-271.
88. Patchev VK, Montkowski A, Rouskova D, et al. Neonatal treatment of rats with the neuroactive steroid tetrahydrodeoxycorticosterone (THDOC) abolishes the behavioral and neuroendocrine consequences of adverse early life events. J Clin Invest. 1997;99:962-966.
89. Dong E, Matsumoto K, Uzunov G, et al. Brain 5alpha-dihydroprogesterone and allopregnanolone synthesis in a mouse model of protracted social isolation. Proc Natl Acad Sci U S A. 2001;98:2849-2854.
90. Klatzkin RR, Morrow AL, Light KC, Pedersen CA, Girdler SS. Histories of depression, allopregnanolone responses to stress, and premenstrual symptoms in women. Biol Psychol. 2006;71:2-11.
91. Rapkin AJ, Morgan M, Goldman L, et al. Progesterone metabolite allopregnanolone in women with premenstrual syndrome. Obstet Gynecol. 1997;90:709-714.
92. Sundström I, Andersson A, Nyberg S, et al. Patients with premenstrual syndrome have a different sensitivity to a neuroactive steroid during the menstrual cycle compared to control subjects. Neuroendocrinology. 1998;67:126-138.
93. Hennings JM, Ising M, Grautoff S, et al. Glucose tolerance in depressed inpatients, under treatment with mirtazapine and in healthy controls. Exp Clin Endocrinol Diabetes. 2010;118:98-100.
94. Kopf D, Westphal S, Luley CW, et al. Lipid metabolism and insulin resistance in depressed patients: significance of weight, hypercortisolism, and antidepressant treatment. J Clin Psychopharmacol. 2004;24:527-531.
95. Weber-Hamann B, Hentschel F, Kniest A, et al. Hypercortisolemic depression is associated with increased intra-abdominal fat. Psychosom Med. 2002;64:274-277.
96. Vogelzangs N, Suthers K, Ferrucci L, et al. Hypercortisolemic depression is associated with the metabolic syndrome in late-life. Psychoneuroendocrinology. 2007;32:151-159.
97. de Leon MJ, McRae T, Rusinek H, et al. Cortisol reduces hippocampal glucose metabolism in normal elderly, but not in Alzheimer's disease. J Clin Endocrinol Metab. 1997;82:3251-3259.
98. McIntyre RS, Soczynska JZ, Lewis GF, et al. Managing psychiatric disorders with antidiabetic agents: translational research and treatment opportunities. Expert Opin Pharmacother. 2006;7:1305-1321.
99. Rasgon NL, Kenna HA. Insulin resistance in depressive disorders and Alzheimer's disease: revisiting the missing link hypothesis. Neurobiol Aging. 2005;26 Suppl 1:103-107.
100. Avogaro A, de Kreutzenberg SV, Fadini GP. Insulin signaling and life span. Pflugers Arch. 2010;459:301-314.
101. Gardner JP, Srinivasan SR, Chen W, et al. Rise in insulin resistance is associated with escalated telomere attrition. Circulation. 2005;111:2171-2177.
102. Alvehus M, Buren J, Sjostrom M, Goedecke J, Olsson T. The human visceral fat depot has a unique inflammatory profile. Obesity (Silver Spring). 2010;18:879-883.
103. Palmieri VO, Grattagliano I, Portincasa, P, Palasciano, G. Systemic oxidative alterations are associated with visceral adiposity and liver steatosis in patients with metabolic syndrome. J Nutr. 2006;136:3022-3026.
104. Bauer ME, Jeckel CM, Luz C. The role of stress factors during aging of the immune system. Ann N Y Acad Sci. 2009;1153:139-152.
105. Kiecolt-Glaser J.K, Glaser R. Depression and immune function: central pathways to morbidity and mortality. J Psychosom Res. 2002;53:873-876.
106. Dhabhar FS, Burke HM, Epel ES, et al. Low serum IL-10 concentrations and loss of regulatory association between IL-6 and IL-10 in adults with major depression. J Psychiatr Res. 2009;43:962-969.
107. Dowlati Y, Hermann N, Swardfager W, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010;67:446-457.
108. Kaur K, Sharma AK, Dhingra S, Singal PK. Interplay of TNF-alpha and IL-10 in regulating oxidative stress in isolated adult cardiac myocytes. J Mol Cell Cardiol. 2006;41:1023-1030.
109. Pickering M. O'Connor J.J. Pro-inflammatory cytokines and their effects in the dentate gyrus. Prog Brain Res. 2007;163:339-354.
110. Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry. 2009;65:732-741.
111. Marsland AL, Gianaros PJ, Abramowitch SM, Manuck SB, Hariri AR. Interleukin-6 covaries inversely with hippocampal grey matter volume in middle-aged adults. Biol Psychiatry. 2008;64:484-490.
112. Carrero JJ, Stenvinkel P, Fellström B, et al. Telomere attrition is associated with inflammation, low fetuin-A levels and high mortality in prevalent haemodialysis patients. J Intern Med. 2008;263:302-312.
113. Effros RB. Kleemeier Award Lecture. 2008--the canary in the coal mine: telomeres and human healthspan. J Gerontol A Biol Sci Med Sci. 2009;64:511-515.
114. Irie M, Miyata M, Kasai H. Depression and possible cancer risk due to oxidative DNA damage. J Psychiatr Res. 2005;39:553-560.
115. Joseph JA, Shukitt-Hale B, Casadesus G, Fisher D. Oxidative stress and inflammation in brain aging: nutritional considerations. Neurochem Res. 2005;30:927-935.
116. Forlenza MJ, Miller GE. Increased serum levels of 8-hydroxy-2'-deoxyguanosine in clinical depression. Psychosom Med. 2006;68:1-7.
117. Wolkowitz OM, Mellon SH, Epel ES, et al. Leukocyte telomere length in major depression: correlations with chronicity, inflammation and oxidative stress - preliminary findings. PLoS One. 2011. In press.
118. Tsirpanlis G, Chatzipanagiotou S, Boufidou F, et al. Serum oxidized low-density lipoprotein is inversely correlated to telomerase activity in peripheral blood mononuclear cells of haemodialysis patients. Nephrology (Carlton). 2006;11:506-509.
119. Grant MM, Barber VS, Griffiths HR. The presence of ascorbate induces expression of brain derived neurotrophic factor in SH-SY5Y neuroblastoma cells after peroxide insult, which is associated with increased survival. Proteomics. 2005;5:534-540.
120. Cumurcu BE, Ozyurt H, Etikan I, Demir S, Karlidag R. Total antioxidant capacity and total oxidant status in patients with major depression: impact of antidepressant treatment. Psychiatry Clin Neurosci. 2009;63:639-645.
121. Groves JO. Is it time to reassess the BDNF hypothesis of depression? Mol Psychiatry. 2007;12:1079-1088.
122. Chen B, Dowlatshahi D, MacQueen GM, Wang J.-F, Young LT. Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol Psychiatry. 2001;50:260-265.
123. Bocchio-Chiavetto L, Bagnardi V, Zanardini R, et al. Serum and plasma BDNF levels in major depression: a replication study and meta-analyses. World J Biol Psychiatry 2010;11:763-773.
124. Schmidt HD, Duman RS. Peripheral BDNF produces antidepressant-like effects in cellular and behavioral models. Neuropsychopharmacology. 2010;35:2378-2391.
125. Santarelli L, Saxe M, Gross C, et al. Requirement of hippocampal neurogenisis for the behavioral effects of antidepressants. Science. 2003;301:805-809.
126. Ibarguen-Vargas Y, Surget A, Touma C, et al. Deficit in BDNF does not increase vulnerability to stress but dampens antidepressant-like effects in the unpredictable chronic mild stress. Behav Brain Res. 2009;202:245-251.
127. Joosten EA, Houweling DA. Local acute application of BDNF in the lesioned spinal cord anti-inflammatory and anti-oxidant effects. Neuroreport. 2004;15:1163-1166.
128. Fu W, Lu C, Mattson MP. Telomerase mediates the cell survival-promoting actions of brain-derived neurotrophic factor and secreted amyloid precursor protein in developing hippocampal neurons. J Neurosci. 2002;22:10710-10719.
129. Chaldakov GN, Tonchev AB, Manni L, et al. Comment on: Krabbe KS, Nielsen AR, Krogh-Madsen R et al. Brain-derived neurotrophic factor (BDNF) and type 2 diabetes. Diabetologia. 2007;50:431-438. Diabetologia. 2007;50:1781-1782.
130. Krabbe KS, Nielsen AR, Krogh-Madsen R, et al. Brain-derived neurotrophic factor (BDNF) and type 2 diabetes. Diabetologia. 2007;50:431-438.
131. Blackburn EH, Greider, CW, Szostak, JW. Telomeres and telomerase: the path from maize, Tetrahymena and yeast to human cancer and aging. Nat Med. 2006;12:1133-1138.
132. Aviv A. Telomeres and human aging: facts and fibs. Sci Aging Knowledge Environ. 2004;51:pe43.
133. Simon NM, Smoller JW, McNamara KL, et al. Telomere shortening and mood disorders: preliminary support for a chronic stress model of accelerated aging. Biol Psychiatry. 2006;60:432-435.
134. Lung FW, Chen NC, Shu BC. Genetic pathway of major depressive disorder in shortening telomeric length. Psychiatr Genet. 2007;17:195-199.
135. Hartmann N, Boehner M, Groenen F, Kalb R. Telomere length of patients with major depression is shortened but independent from therapy and severity of the disease. Depress Anxiety. 2010;27:1111-1116.
136. Epel ES, Merkin SS, Cawthon R, et al. The rate of leukocyte telomere shortening predicts mortality from cardiovascular disease in elderly men. Aging. 2009;1:81-88.
137. Cawthon RM, Smith KR, O'Brien E, Sivatchenko A, Kerber RA. Association between telomere length in blood and mortality in people aged 60 years or older. Lancet. 2003;361:393-395.
138. Damjanovic AK, Yang Y, Glaser R, et al. Accelerated telomere erosion is associated with a declining immune function of caregivers of Alzheimer's disease patients. J Immunol. 2007;179:4249-4254.
139. Wolkowitz OM, Mellon SH, Epel ES, et al. Resting leukocyte telomerase activity is elevated in major depression and predicts treatment response. Mol Psychiatry. 2011. In press.
140. Choi J, Fauce SR, Effros RB. Reduced telomerase activity in human T lymphocytes exposed to cortisol. Brain Behav Immun. 2008;22:600-605.
141. Liu JP, Chen SM, Cong YS, et al. Regulation of telomerase activity by apparently opposing elements. Ageing Res Rev. 2010;9:245-256.
142. Epel E, Daubenmier J, Moskowitz JT, Folkman S, Blackburn E. Can meditation slow rate of cellular aging? Cognitive stress, mindfulness, and telomeres. Ann N Y Acad Sci. 2009;1172:34-53.
143. Mattson MP, Duan W, Wan R, Guo Z. Prophylactic activation of neuroprotective stress response pathways by dietary and behavioral manipulations. NeuroRx. 2004;1:111-116.
144. Spires TL. Hannan AJ. Nature, nurture and neurology: gene-environment interactions in neurodegenerative disease. FEBS Anniversary Prize Lecture, delivered on 27 June, 2004 at the 29th FEBS Congress in Warsaw. Febs J. 2005;272:2347-2361.
145. Maes M, Yirmyia R, Noraberg J, et al. The inflammatory neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression. Metab Brain Dis. 2009;24:27-53.
146. McIntyre RS, Soczynska JK, Woldeyohannes HO, et al. Thiazolidinediones: novel treatments for cognitive deficits in mood disorders? Expert Opin Pharmacother. 2007;8:1615-1628.
147. Sanacora G, Zarate CA, Krystal JH, Manji HK. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov. 2008:7:426-437.
148. Paul IA. Antidepressant activity and calcium signaling cascades. Hum Psychopharmacol. 2001;16:71-80.
149. Berthold-Losleben M, Heitmann S, Himmerich H. Anti-inflammatory drugs in psychiatry. Inflamm Allergy Drug Targets. 2009;8:266-276.
150. Berk M, Copolov DL, Dean O, et al. N-acetyl cysteine for depressive symptoms in bipolar disorder--a double-blind randomized placebo-controlled trial. Biol Psychiatry. 2008;64:468-475.
151. Zhang Y, Pardridge WM. Conjugation of brain-derived neurotrophic factor to a blood-brain barrier drug targeting system enables neuroprotection in regional brain ischemia following intravenous injection of the neurotrophin. Brain Res. 2001;889:49-56.
152. Effros RB. Telomerase induction in T cells: A cure for aging and disease? Exp Gerontol. 2007;42:416-420.
153. Harley CB, Liu W, Blasco M, et al. A natural product telomerase activator as part of a health maintenance program. Rejuvenation Res. In press.
154. Ornish D, Scherwitz LW, Doody RS, et al. Effects of stress managment training and dietary changes in treating ischemic heart disease. JAMA. 1983;249:54-59.
155. Hajkova P. Epigenetic reprogramming--taking a lesson from the embryo. Curr Opin Cell Biol. 2010;22:342-350.
156. Weaver IC, Champagne FA, Brown SE, et al. Reversal of maternal programming of stress responses in adult offspring through methyl supplementation: altering epigenetic marking later in life. J Neurosci. 2005:25:11045-11054.
157. Holsboer F, Ising M. Central CRH system in depression and anxiety--evidence from clinical studies with CRH1 receptor antagonists. Eur J Pharmacol. 2008;583:350-357.
158. Cocchi P, Silenzi M, Calabri G, Salvi G. Antidepressant effect of vitamin C. Pediatrics. 1980;65:862-863.